Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II alectinib in advanced ALK-rearranged NSCLC detected by liquid biopsy
jRCT2080225060Phase 2Completed
- Sponsor
- National Cancer Center Hospital East
- Start
- Feb 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of alectinib in non-small cell lung cancer (NSCLC), sponsored by National Cancer Center Hospital East. Started Feb 2020; status: completed.
02
Drugs
alectinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2080225060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225060.